Vir Biotechnology, Inc. Increase (Decrease) in Deferred Revenue
Vir Biotechnology, Inc. (VIR) reported Increase (Decrease) in Deferred Revenue of -$3.21 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2025-11-05
- Vir Biotechnology, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$675.00K.
- Vir Biotechnology, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-06-30 was -$1.83M, a 479.05% decline year-over-year.
- Vir Biotechnology, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-03-31 was -$713.00K.
- Vir Biotechnology, Inc. increase (decrease) in deferred revenue for the quarter ending 2024-12-31 was -$2.55M.
- Vir Biotechnology, Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$53.73M.
- Vir Biotechnology, Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$2.35M.
- Vir Biotechnology, Inc. increase (decrease) in deferred revenue for fiscal 2022 was -$33.30M, a 136.18% decline from fiscal 2021.
- Vir Biotechnology, Inc. increase (decrease) in deferred revenue for fiscal 2021 was $92.04M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$675.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$2.50M derived: sum of 2 quarters · filed 2025-11-05 | -$3.21M 10-Q · filed 2025-11-05 | -$5.76M derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | -$1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$2.54M 10-Q · filed 2025-08-06 | -$5.09M derived: sum of 3 quarters · filed 2025-08-06 | -$6.59M derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-03-31 | -$713.00K 10-Q · filed 2025-05-08 | -$3.26M derived: sum of 2 quarters · filed 2025-05-08 | -$4.77M derived: sum of 3 quarters · filed 2025-11-05 | -$4.29M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-12-31 | -$2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$4.05M derived: sum of 2 quarters · filed 2025-11-05 | -$3.57M derived: sum of 3 quarters · filed 2025-11-05 | -$53.73M 10-K · filed 2025-02-27 |
| 2024-09-30 | -$1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.02M derived: sum of 2 quarters · filed 2025-11-05 | -$51.18M 10-Q · filed 2025-11-05 | -$53.32M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $482.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$49.68M 10-Q · filed 2025-08-06 | -$51.82M derived: sum of 3 quarters · filed 2025-08-06 | -$52.19M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$50.16M 10-Q · filed 2025-05-08 | -$52.30M derived: sum of 2 quarters · filed 2025-05-08 | -$52.67M derived: sum of 3 quarters · filed 2025-05-08 | -$54.20M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$2.51M derived: sum of 2 quarters · filed 2025-02-27 | -$4.04M derived: sum of 3 quarters · filed 2025-02-27 | -$2.35M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$369.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$1.91M derived: sum of 2 quarters · filed 2024-11-04 | -$205.00K 10-Q · filed 2024-11-04 | -$9.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $164.00K 10-Q · filed 2024-08-01 | -$8.63M derived: sum of 3 quarters · filed 2025-02-27 | -$48.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.70M 10-Q · filed 2024-05-03 | -$7.09M derived: sum of 2 quarters · filed 2025-02-27 | -$47.16M derived: sum of 3 quarters · filed 2025-02-27 | -$49.18M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$8.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$48.86M derived: sum of 2 quarters · filed 2025-02-27 | -$50.88M derived: sum of 3 quarters · filed 2025-02-27 | -$33.30M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$40.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$42.08M derived: sum of 2 quarters · filed 2023-11-03 | -$24.51M 10-Q · filed 2023-11-03 | -$22.02M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $15.56M 10-Q · filed 2023-08-04 | $18.04M derived: sum of 3 quarters · filed 2024-02-26 | $17.15M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $17.58M 10-Q · filed 2023-05-08 | $20.06M derived: sum of 2 quarters · filed 2024-02-26 | $19.17M derived: sum of 3 quarters · filed 2024-02-26 | $74.22M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.59M derived: sum of 2 quarters · filed 2024-02-26 | $56.65M derived: sum of 3 quarters · filed 2024-02-26 | $92.04M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$893.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $54.16M derived: sum of 2 quarters · filed 2022-11-03 | $89.56M 10-Q · filed 2022-11-03 | $88.26M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $55.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $90.45M 10-Q · filed 2022-08-09 | $89.16M derived: sum of 3 quarters · filed 2023-02-28 | $87.42M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $35.40M 10-Q · filed 2022-05-05 | $34.10M derived: sum of 2 quarters · filed 2023-02-28 | $32.36M derived: sum of 3 quarters · filed 2023-02-28 | $31.54M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$3.03M derived: sum of 2 quarters · filed 2023-02-28 | -$3.85M derived: sum of 3 quarters · filed 2023-02-28 | -$7.04M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$2.56M derived: sum of 2 quarters · filed 2021-11-04 | -$5.75M 10-Q · filed 2021-11-04 | -$4.13M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$822.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$4.01M 10-Q · filed 2021-08-05 | -$2.39M derived: sum of 3 quarters · filed 2022-02-28 | -$3.38M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$3.19M 10-Q · filed 2021-05-06 | -$1.57M derived: sum of 2 quarters · filed 2022-02-28 | -$2.56M derived: sum of 3 quarters · filed 2022-02-28 | $3.71M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $627.00K derived: sum of 2 quarters · filed 2022-02-28 | $6.90M derived: sum of 3 quarters · filed 2022-02-28 | $3.53M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$994.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $5.28M derived: sum of 2 quarters · filed 2020-11-10 | $1.91M 10-Q · filed 2020-11-10 | -$992.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $6.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $2.90M 10-Q · filed 2020-08-11 | $2.00K derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$3.37M 10-Q · filed 2020-05-12 | -$6.27M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $7.87M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $10.77M 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | $888.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |